Trials / Terminated
TerminatedNCT04140695
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
A Randomized, Double-blind, Placebo-controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tradipitant | BID |
| DRUG | Placebo | BID |
Timeline
- Start date
- 2019-10-21
- Primary completion
- 2020-10-14
- Completion
- 2020-10-14
- First posted
- 2019-10-28
- Last updated
- 2024-05-14
- Results posted
- 2024-05-14
Locations
51 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04140695. Inclusion in this directory is not an endorsement.